Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Deloitte
Boehringer Ingelheim
Teva
Julphar
Federal Trade Commission
AstraZeneca
Daiichi Sankyo
Farmers Insurance
Argus Health

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,987,102

« Back to Dashboard

Which drugs does patent 6,987,102 protect, and when does it expire?

Patent 6,987,102 protects MOZOBIL and is included in one NDA.

This patent has thirty-seven patent family members in twenty-six countries.
Summary for Patent: 6,987,102
Title:Methods to mobilize progenitor/stem cells
Abstract:Certain nitrogen-containing compounds that bind the chemokine receptor CXCR4 are able to mobilize progenitor and/or stem cells into the peripheral blood to permit harvesting them for stem cell transplantation.
Inventor(s): Bridger; Gary J. (Bellingham, WA), Abrams; Michael J. (Custer, WA), Henson; Geoffrey W. (Ferndale, WA), MacFarland; Ronald Trevor (Vancouver, CA), Calandra; Gary B. (Cresco, PA), Broxmeyer; Hal E. (Indianapolis, IN), Dale; David C. (Seattle, WA)
Assignee: Anormed, Inc. (Langley, CA)
Application Number:10/209,001
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 6,987,102

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Genzyme MOZOBIL plerixafor SOLUTION;SUBCUTANEOUS 022311-001 Dec 15, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe USE IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELLS TO PERIPHERAL BLOOD FOR COLLECTION & SUBSEQUENT AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA & MULTIPLE MYELOMA ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,987,102

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,169,750 Methods to mobilize progenitor/stem cells ➤ Subscribe
7,897,590 Methods to mobilize progenitor/stem cells ➤ Subscribe
7,935,692 Methods to mobilize progenitor/stem cells ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,987,102

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 538785 ➤ Subscribe
Australia 2002318927 ➤ Subscribe
Brazil 0211570 ➤ Subscribe
Canada 2455559 ➤ Subscribe
Canada 2522048 ➤ Subscribe
China 102302493 ➤ Subscribe
China 1561208 ➤ Subscribe
Cyprus 1112633 ➤ Subscribe
Germany 122012000044 ➤ Subscribe
Denmark 1411918 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Teva
Queensland Health
Covington
Fuji
US Department of Justice
Fish and Richardson
Farmers Insurance
Chinese Patent Office
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot